VRTX
Vertex Pharmaceuticals
NASDAQ: VRTX · Boston, MA · Healthcare
$523.93-11.24 (-2.10%)Closed
Market Cap$112.00B
Cash$13.80Bmost recent
Runwayprofitable
P/E (TTM)29.5EPS $14.72
52-Wk Range$409.47 – $557.96
Avg Volume1.4M3-month
Healthstrong
Commercial-stage biotech with a dominant cystic fibrosis franchise, expanding into pain, T1D, and sickle cell via Casgevy.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$523.93+11.0%
Pipeline
Drug candidates sponsored by Vertex Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Suzetrigine | Acute Pain+2 more | Recruiting | 2027-04-06 | 6 | |
| Phase 3 | Pegylated Interferon Alfa 2a | Hepatitis C | Completed | 2010-05past | 1 | |
| Phase 3 | telaprevir | Hepatitis C | Completed | 2010-06past | 3 | |
| Phase 2 | VX-509 | Rheumatoid Arthritis+1 more | Completed | 2014-07past | 2 | |
| Phase 3 | Lumacaftor Plus Ivacaftor Combination | Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation | Completed | 2016-04past | 1 | |
| Phase 3 | VX-809 | Cystic Fibrosis | Completed | 2016-09past | 3 | |
| Phase 3 | Lumacaftor | Cystic Fibrosis+1 more | Completed | 2016-10past | 4 | |
| Phase 3 | VX-661/Ivacaftor | Cystic Fibrosis | Completed | 2017-02past | 1 | |
| Phase 3 | Ivacaftor | Cystic Fibrosis | Completed | 2017-09past | 5 | |
| Phase 3 | Tezacaftor/Ivacaftor | Cystic Fibrosis | Completed | 2018-08-09past | 3 | |
| Phase 3 | VX-445/TEZ/IVA | Cystic Fibrosis | Completed | 2018-12-28past | 1 | |
| Phase 3 | TEZ/IVA | Cystic Fibrosis | Completed | 2020-10-28past | 3 | |
| Phase 3 | LUM/IVA | Cystic Fibrosis | Completed | 2023-08-22past | 3 | |
| Phase 3 | Suzetrigine (SUZ) | Acute Pain | Completed | 2023-08-25past | 1 | |
| Phase 2 | Exa-cel | Sickle Cell Disease+2 more | Completed | 2025-07-07past | 1 | |
| Phase 3 | ELX/TEZ/IVA | Cystic Fibrosis | Completed | 2026-01-29past | 6 | |
| Phase 3 | VX-880 | Diabetes Mellitus, Type 1+2 more | Recruiting | 2027-12-31 | 1 | |
| Phase 2 | VX-147 | Proteinuric Kidney Disease | Active, not recruiting | 2028-06-02 | 1 | |
| Phase 2 | Povetacicept | Primary Membranous Nephropathy+1 more | Recruiting | 2028-12-29 | 2 | |
| Phase 3 | VNZ/TEZ/D-IVA | Cystic Fibrosis | Completed | 2029-07-30 | 2 | |
| Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | Active, not recruiting | 2030-06-30 | 2 | |
| Phase 3 | CTX001 | Beta-Thalassemia+6 more | Enrolling | 2039-09-30 | 1 | |
| Phase 2 | Ribavirin | Chronic Hepatitis C | Completed | 2008-05past | 1 | |
| Phase 2 | Ivacaftor 25 mg/75 mg | Cystic Fibrosis | Completed | 2008-08past | 1 | |
| Phase 2 | AVN944 | Pancreatic Cancer+1 more | Terminated | 2010-03past | 2 | |
| Phase 1 | VCH-222 or matching placebo | Hepatitis C | Completed | 2012-09past | 1 | |
| Phase 2 | VX-787 | Influenza Virus | Completed | 2012-10past | 1 | |
| Phase 2 | VX-770 | Cystic Fibrosis | Completed | 2013-02past | 2 | |
| Phase 2 | VX-222 | Chronic Hepatitis C Virus | Completed | 2013-06past | 1 | |
| Phase 2 | VX-135 | Chronic Hepatitis C+3 more | Completed | 2014-05past | 1 | |
| Phase 2 | VX-150 | Osteoarthritis+1 more | Completed | 2019-01-17past | 2 | |
| Phase 1 | Placebo (matched to VX-121 suspension) | Cystic Fibrosis | Completed | 2019-05-03past | 1 | |
| Phase 2 | VX-121 | Cystic Fibrosis | Completed | 2019-12-10past | 1 | |
| Phase 2 | VX-561 | Cystic Fibrosis | Completed | 2020-08-20past | 2 | |
| Phase 2 | VX-814 | Alpha 1-Antitrypsin Deficiency | Terminated | 2020-11-14past | 1 | |
| Phase 2 | VX-864 | Alpha1-Antitrypsin Deficiency | Completed | 2021-05-04past | 1 | |
| Phase 2 | VX-548 | Acute Pain+1 more | Completed | 2023-07-24past | 4 | |
| Phase 2 | VX-993 | Acute Pain+1 more | Completed | 2025-05-27past | 2 | |
| Phase 2 | VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Recruiting | 2027-03-11 | 3 | |
| Phase 1 | VX-264 | Type 1 Diabetes | Active, not recruiting | 2027-03-12 | 1 | |
| Phase 2 | VX-670 | Myotonic Dystrophy Type 1 (DM1) | Enrolling | 2029-01-30 | 1 | |
| Phase 2 | VX-702 | Rheumatoid Arthritis | Completed | — | 1 | |
| Phase 2 | Merimepodib | Hepatitis C+1 more | Completed | — | 1 | |
| Phase 2 | VX-765 | Psoriasis | Completed | — | 1 | |
| Phase 1 | telaprevir (VX-950) | Hepatic Insufficiency | Completed | 2008-06past | 1 | |
| Phase 1 | VCH 916 | HCV Infection | Completed | 2008-10past | 1 | |
| Phase 1 | VCH-222 | Hepatitis C | Completed | 2010-01past | 1 | |
| Phase 1 | lumacaftor 200 mg q12h + ivacaftor 250 mg q12h | Hepatic Impairment+1 more | Completed | 2013-11past | 1 | |
| Phase 1 | VX-440 | Cystic Fibrosis | Completed | 2016-09-14past | 1 | |
| Phase 1 | VX-708 | Acute Pain | Completed | 2023-04-14past | 1 | |
| Phase 1 | IXP | Renal Impairment+1 more | Completed | 2024-12-20past | 2 | |
| Phase 1 | SUZ | Pain | Completed | 2025-04-24past | 1 | |
| Phase 1 | VX-828 | Cystic Fibrosis | Completed | 2025-05-05past | 1 | |
| Phase 1 | VX-973 | Pain | Completed | 2025-07-21past | 1 | |
| Phase 1 | 14C-VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Not yet recruiting | 2026-12-15 | 1 | |
| Phase 1 | VX-272 | Cystic Fibrosis | Recruiting | 2027-06-26 | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2019-12past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2025-11-27past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.